Maximizing imaging techniques to bridge the gap between diagnosis and treatment of cancer

Glioblastoma multiforme is the most common form of brain cancer and patients with this diagnosis have a life expectancy of less than two years. In spite of the fact that its diagnosis is very good, an appropriate treatment remains elusive.

Bruker, one of the world's leading analytical instrumentation companies will present an informative webinar on preclinical imaging techniques that enable the effective testing of treatments.

The online event will offer new insights in the use of animal models as a basis for treatment testing, explaining how the models must be established to closely mirror the clinical cases to enable treatment research.

The free 45 minute webinar will give you an invaluable insight into current research by renowned scientists who are using animal models for preclinical research. The webinar will equip with you an understanding of both the requirements and the benefits of using Magnetic Resonance Imaging (MRI)  for glioblastoma and additional forms of cancer, together with an informative overview of compact MRI.

Bruker invites any interested doctors and scientists working in the medical field, in imaging, in health and disease related research or pharmaceuticals to register for the free online event, taking place on Tuesday 18th March.

Oncology labs are bringing the power of Preclinical MRI to bear in the goal to bridge the still significant gap between diagnostics and treatment. This webinar will illustrate the ability of today’s imaging technologies to provide quick, accurate and detailed answers to treatment questions.

The seminar is available in two sessions on the day, starting at 10.00 am and 5.00 pm CET time.

Those unable to attend the event are given the opportunity to register anyway and have the webinar slides and a link to a recording of the event sent to them for viewing at a more convenient time.

Register now to Session 1 (10:00 AM CET) or Session 2 (5:00 PM CET).